Previous statins treatment and risk of post-stroke infections

Neurologia. 2011 Apr;26(3):150-6. doi: 10.1016/j.nrl.2010.07.030. Epub 2010 Nov 13.
[Article in English, Spanish]

Abstract

Introduction: Clinical and laboratory studies have attributed an inmuno-supressor effect to the statins. Furthermore, the administration of simvastatin in the acute onset of stroke has been associated with an increased infection frequency. Our objective is to assess the influence of statins previous treatment on infection after ischemic stroke.

Patients and methods: Observational study of patients with ischaemic stroke hospitalised in a Stroke Unit. Demographic data, vascular risk factors, stroke severity, stroke subtype and previous statins treatment were evaluated. The following infections were registered: pneumonia, urinary tract infection, pseudomembranous colitis and sepsis. The patients were classified into two groups, depending on previous statin treatment.

Results: A total of 2045 patients were included (1165 were male, aged 69.05±12.5 years). Of these, 306 (15%) patients were receiving statins prior to stroke. These patients had more frequently arterial hypertension, DM, peripheral arterial disease and hypercholesterolaemia than the patients who were not treated with statins (P<0001). There was no statistically significant difference between overall in-hospital infection frequency between patients treated with statins and those with no statins treatment, (11.8% vs. 13%), nor in individual infection type: pneumonia (7.8% vs. 10.2%), urinary tract infection (4.2% vs. 2.8%), pseudomembranous colitis (0.3% vs. 0.7%) and sepsis (2.6% vs. 4.4%). In the atherothrombotic stroke subtype, statins were associated with a lower frequency of sepsis (unadjusted OR, 0.949; 95% CI; 0.928-0.971).

Conclusions: Previous treatment with statins does not appear to influence the frequency of in-hospital infections in patients with ischaemic stroke.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Infections / chemically induced*
  • Infections / epidemiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors
  • Stroke / drug therapy*
  • Young Adult

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors